FDA Announces Enforcement Discretion for Certain Unclassified Medical Devices

The U.S. Food and Drug Administration has published updated guidance announcing its intent to exempt certain unclassified medical devices from premarket notification requirements, commonly known as 510(k) requirements. The guidance, effective immediately, reflects the FDA’s current assessment that the identified devices meet the standards for exemption and represents a continued effort to reduce regulatory burden on manufacturers of lower-risk products.

Until formal exemption is enacted or until the FDA becomes aware of new information affecting its assessment the agency does not intend to enforce 510(k) compliance for these devices. Manufacturers of the included device types are not expected to submit premarket notifications during this period.

The updated guidance supersedes the June 2019 version of the same title and adds five new product codes that have been independently reviewed and recommended for classification into Class I or Class II:

• LDK — Device, sensing, optical contour

• MVV — Device, acupressure

• MQZ — Prosthesis, nail

• MIG — Strip, test isoniazid

• LXQ — Cup, eye

For manufacturers producing or importing any of the five newly identified device types, the practical effect of this guidance is significant: 510(k) submissions are not required while the enforcement discretion policy is in place. This reduces premarket compliance costs and timelines for bringing these products to the U.S. market.

However, manufacturers should note that this guidance does not confer legal rights and is not binding on the FDA. The agency retains the authority to revise or withdraw the guidance if new safety information emerges. Companies should continue to monitor the Federal Register and FDA guidance updates for any changes affecting their product categories.

The FDA’s commitment to propose low-risk medical devices for 510(k) exemption originated in the reauthorization process for the Medical Device User Fee Amendments of 2012. The exemption process reflects the agency’s broader goal of focusing premarket review resources on higher-risk devices while reducing unnecessary regulatory requirements for products with well-established safety profiles.

The guidance was implemented without prior public comment under applicable FDA procedures, but remains open to comment in accordance with the agency’s good guidance practices. Comments can be submitted to the FDA through its standard guidance comment process.

FDA regulatory changes affecting medical device classifications can have direct implications for import compliance, HTS classification, and CBP entry procedures. Alba’s trade compliance team helps medical device importers and manufacturers navigate the intersection of FDA requirements and U.S. customs obligations.

Contact our team to learn how these developments could impact your business: https://albawheelsup.com/contact/